Since then, various Novobiocin analogues have been developed which show strong anti-proliferation activity in prostate cancer lines [139,141] or show potential neuroprotective properties and provide avenues where Hsp90 inhibition can be studied in the context of neurodegeneration [138]. This evidence concerns the gene HSP90AA1 and prostate carcinoma.